Vistara gets another Rs 750-crore fund infusion from Tata Sons, Singapore Airlines

In the latest round of fund infusion, Tata Sons would infuse Rs 382.5 crore in Vistara while Singapore Airlines would infuse Rs 367.5 crore.

Yaruqhullah Khan

August 10, 2021 / 20:21 IST

Tata Sons Ltd, the holding company of Tata group, and Singapore Airlines Ltd - the two promoters of Vistara - have infused an additional Rs 750 crore into the airline, data accessed by the business intelligence platform Tofler showed.

In the latest round of fund infusion, Tata Sons Pvt Ltd will infuse Rs 382.5 crore in Vistara while Singapore Airlines Ltd will infuse Rs 367.5 crore, data from Tofler, which was reviewed by Moneycontrol, showed.

The new fund infusion comes just three months after the airline's promoters had infused Rs 465 crore in Vistara back in May.

The airline’s board has also approved the allotment of 75 crore shares of Rs 10 each to the two promoters. A Vistara spokesperson declined to comment on the fundraising but said the airline continued to grow its operations.

The fresh equity infusion comes at a time when the aviation industry is struggling to stay afloat due to travel restrictions across the country coupled with the restrictions on flight capacity and seat pricing set by the government of India.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show